Qlife has today called for an EGM because it is obliged to do so when the company has written down half of its equity as previously communicated in connection with the company’s year-end report for the financial year 2023.
The management previously has stated that it is not in agreement with this write-down – there has been extensive ongoing discussions with the auditors regarding the valuation of the company. The management do not perceive the year-end value as indicative of the true value of the company.
“We are working full speed to execute on our plans as has been previously communicated, nothing has changed in this regard – the call for EGM at this time is a necessity to fulfill law requirements” says Thomas Warthoe, CEO of Qlife
For more information, please contact:
Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
E-mail: tw@egoo.health
Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.